0,1,2,3,4,5,6,7
Table 6.1.7: Major phase III randomised trials of moderate hypofractionation for primary treatment,,,,,,,
Study/  Author,n,"Risk, ISUP   grade, or   NCCN",ADT,RT Regimen,"BED, Gy Median","FU, mo",Outcome
"Lee, et al.   2016 [660]",550   542,low risk,None,70 Gy/28 fx   73.8 Gy/41 fx,80   69.6,70,5 yr. DFS 86.3%   (n.s.)   5 yr. DFS 85.3%
"Dearnaley,   et al. CHHiP   2016 [661]","1,077/19 fx   1,074/20 fx   1,065/37 fx",15% low   73%   intermediate   12% high,3-6 mo.   before   and   during   EBRT,57 Gy/19 fx   60 Gy/20 fx   74 Gy/37 fx,73.3   77.1   74,62,5 yr. BCDF   85.9% (19 fx)   90.6% (20 fx)   88.3% (37 fx)
"De Vries,   et al., 2020   [667]",403   392,"30% ISUP   grade 1   45% ISUP   grade 2-3,   25% ISUP   grade 4-5",None,64.6 Gy/19 fx   78 Gy/39 fx,90.4   78,89,8-yr. OS 80.8%   vs. 77.6%  (p = 0.17)  8 yr. TF 24.4%   vs. 26.3%
"Catton, et al.   2017 [663]",608,intermediate   risk   53% T1c   46% T2a-c,None,60 Gy/20 fx,77.1,72,5 yr. BCDF both   arms 85%   HR: 0.96 (n.s)
,598,9% ISUP   grade 1   63% ISUP   grade 2   28% ISUP   grade 3,,78 Gy/39 fx,78,,
